You are here

Boronated Asparagine and Glutamine Analogs for BNCT

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 CA65433-1,
Agency Tracking Number: 24937
Amount: $79,380.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1994
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
620 Hutton Street, Suite 104
Raleigh, NC 27606
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Bernard Spielvogel
 (919) 832-2044
Business Contact
Phone: () -
Research Institution
N/A
Abstract

Boron Neutron Capture Therapy (BNCT) has a clear theoretical advantage over other techniquesas a method of delivering cell-killing radiation to tumors. The inability of leukemia cells to synthesizeasparagine and the requirement of exogeneous asparagine by tumor cells provide an excellentopportunity for exploitation by BNCT, using boron analogs. Boronic acids are also good inhibitors ofserine proteases and good analogs of transition states in enzymatic reactions, Boron-containing transitionstate analogs of asparagine and glutamine could use the inhibition mechanism to control tumorproliferation. Incorporation of boron into tumor cell can pave way for cell destruction by BNCT. PhaseI research will focus on the synthesis of (i) boron-containing transition state analogs of asparagine andglutamine, (ii) a delta-boronated amino acid, and evaluation of their cytotoxicity and in vitro efficacy.Phase II effort will focus on (i) synthesis of other boronated amino acid analogs and their peptides, (ii)further in vitro toxicity, in vivo efficacy studies, and (iii) BNCT, antineoplastic activity and long termtoxicity of lead compounds.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government